Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MONTBLANC triple immunotherapy and bevacizumab study in unresectable hepatocellular carcinoma
2024-511439-84-00Phase 2Authorised
- Sponsor
- LMU Klinikum
- Start
- Mar 2023
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of durvalumab, tremelimumab and bevacizumab in hepatocellular carcinoma (HCC) (2 arms), sponsored by LMU Klinikum. Primary endpoint: Objective response rate. Planned start Mar 2023; status: authorised.
02
Drugs
durvalumabtremelimumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2024-511439-84-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511439-84-00.